Format

Send to:

Choose Destination
See comment in PubMed Commons below
Blood. 2011 Oct 13;118(15):4041-52. doi: 10.1182/blood-2011-03-278127. Epub 2011 Aug 9.

How I treat hemophagocytic lymphohistiocytosis.

Author information

  • 1Divisions of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of pathologic immune activation, occurring as either a familial disorder or a sporadic condition, in association with a variety of triggers. This immune dysregulatory disorder is prominently associated with cytopenias and a unique combination of clinical signs and symptoms of extreme inflammation. Prompt initiation of immunochemotherapy is essential for survival, but timely diagnosis may be challenging because of the rarity of HLH, its variable presentation, and the time required to perform diagnostic testing. Therapy is complicated by dynamic clinical course, high risk of treatment-related morbidity, and disease recurrence. Here, we review the clinical manifestations and patterns of HLH and describe our approach to the diagnosis and therapy for this elusive and potentially lethal condition.

PMID:
21828139
[PubMed - indexed for MEDLINE]
PMCID:
PMC3204727
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk